Takeda Pharmaceutical (TAK) Net Cash Flow Growth (1y) (2019 - 2026)
Takeda Pharmaceutical (TAK) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn | -1,020.00% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 383.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209.30% |
| Dec 31, 2025 | 87.52% |
| Sep 30, 2025 | 236.20% |
| Jun 30, 2025 | -110.65% |
| Mar 31, 2025 | -160.72% |
| Dec 31, 2024 | -1,318.55% |
| Sep 30, 2024 | 4,081.95% |
| Jun 30, 2024 | 225.27% |
| Mar 31, 2024 | 193.67% |
| Dec 31, 2023 | 75.44% |
| Sep 30, 2023 | -101.57% |
| Jun 30, 2023 | 3.25% |
| Mar 31, 2023 | -225.31% |
| Dec 31, 2022 | -175.43% |
| Sep 30, 2022 | 340.06% |
| Jun 30, 2022 | 39.15% |
| Mar 31, 2022 | -70.18% |
| Dec 31, 2021 | 1,100.34% |
| Sep 30, 2021 | -194.16% |
| Jun 30, 2021 | -568.46% |